GJB5 Association with BRAF Mutation and Survival in Cutaneous Malignant Melanoma

Researchers investigated Connexin 31.1 (GJB5) expression and identified any association with BRAF mutational status, melanoma patient prognosis and MAPK inhibitors treatment.